StarFish Medical

VANCOUVER, BC - Biolux Research Ltd. is pleased to announce that it has received the prestigious red dot product design award for the OsseoPulse™ Bone Regeneration System, in recognition of the innovative design of the medical product.

Since 1955, the Design Zentrum Nordrhein Westfalen has been marking outstanding international product design with its famous red dot. Manufacturers and designers of a wide variety of industrial products enter their work all year round in different product groups for the coveted red dot award. This year approximately 1,636 companies from 57 countries have taken part with a total of 4,252 entries submitted for review by an internationally renowned expert jury. Design awards are given in 17 different product categories, including medical equipment and machinery, resulting in publication in a yearbook and an online directory of winning products. The OsseoPulse™ was awarded an honourable mention in the red dot award: product design 2010. More information on the red dot organization, award process and winners can be found at www.red-dot.de.

“We are very pleased with receiving this prestigious design award, in recognition of the efforts invested in the product design by our team, and the resulting innovation of the OsseoPulse™. To be listed amongst the winners with such leaders in the medical device industries is very rewarding,” states Kevin Strange, President and CEO of Biolux. “I would like to thank Dr. Peter Brawn, founder of Biolux, for his guiding vision for the OssePulse™, the designers and engineers at StarFish Medical for their expertise in the conceptual, industrial, and product design of the OsseoPulse™, and our clinical investigators for their key contributions in the evaluation and evolution of this award-winning product.”

About Biolux Research
Biolux Research Ltd. is a world leader in the development of Light Accelerated Bone Regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research, and its proprietary, patentpending OsseoPulse™ Bone Regeneration System has been developed to enhance clinical outcomes in implantology and oral surgery by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

About StarFish Medical
Starfish Medical is a leading specialist firm in contract medical device development and manufacturing with 45 staff headquartered in Victoria, BC, Canada. For over 10 years StarFish Medical has been combining high technology solutions and human-centric design capabilities to create successful products. StarFish is ISO 13485 certified and serves clients all over North America. www.starfishmedical.com

For more information:
Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120

VICTORIA, BC - StarFish Medical is proud to announce it has won the Team of the Year Award at the 2009 VIATeC Tech Awards night. This award recognizes an individual or a team in the Vancouver Island technology sector which has demonstrated outstanding initiative and service delivery, and has had a significant impact on the company for which they work.  The Vancouver Island technology sector presently has over 900 companies with 13,000 employees and over $1.7 billion in annual revenues.

For StarFish Medical, the winning team comprised Mechanical Engineers, Industrial Designers and an Engineering Physicist who combined their skills to transform a proof of concept device DNA separation device into an operable, marketable alpha prototype for their client, Boreal Genomics, within a 3-month timeframe.

Boreal Genomics was able to demonstrate their device at a key conference in their sector which generated significant attention and ultimately resulted in additional capital both from grants and investment to expand their business.

"In an incredibly short time, and very cost effectively, StarFish engineers helped us to develop an instrument that completely changed the way our company is perceived," says Dr. Andre Marziali, the Chief Scientist at Boreal Genomics. "We will certainly work with Starfish again on our next instrument iteration, and can safely say that if our company is successful, they will have played a substantially enabling role."

Scott Phillips, President of StarFish Medical, says, "I believe the success of the Boreal Genomics project reflects the quality and commitment of the team at StarFish and their ability to provide excellent results."

You can view the team receiving the award on YouTube - http://www.youtube.com/watch?v=No3YttxmWFU

About Boreal Genomics
Boreal Genomics is a biotechnology instrument research and development company which is a spin-off from University of British Columbia. Boreal Genomics?s instruments are based on SCODA: a novel, proprietary electrophoresis technology that selectively concentrates nucleic acids.  Read more about Boreal Genomics at www.borealgenomics.com/products.html

About StarFish Medical
For more than ten years, StarFish has provided practical and innovative solutions in all aspects of medical device design and manufacturing, from product definition and technical engineering to formal product development and volume production in a quality environment. StarFish, an ISO 13485 certified company, provides practical turnkey to medical device companies all over North America.  The company’s cross-functional team offers expertise in engineering physics, electronics, software, firmware, mechanical engineering, industrial design and manufacturing transfer.  More information is available at StarFish Medical.

For more information contact:
Scott Phillips, President
www.starfishmedical.com
250.388.3537

25-year leader in heart valve testing systems under new management

VICTORIA, BC - StarFish Medical today announced that it has purchased the product lines of ViVitro Systems Inc., a 25-year old, privately held Victoria company.  ViVitro offers industry leading prosthetic heart valve test equipment and related testing and consulting services worldwide.  The agreement ensures continuity for the company's customers and holds a promising future for the further development of the product line and testing services. ViVitro equipment will continue to be sold under the current brand.

StarFish president Scott Phillips sees the deal as a perfect fit, since it leverages the core expertise of StarFish in medical device development and manufacturing and builds on the good reputation ViVitro has established over the years.  The ViVitro assets will be rolled into a new wholly-owned subsidiary of StarFish.  Founding partners David Walker, Ph.D. and Larry Scotten, Dipl. T., will provide product support during the transition and will continue offering research and testing services for a limited time.

StarFish Medical intends to evolve the current product line and to more actively market it to worldwide clients from medical device companies to universities and regulatory bodies. 

The heart valve market and demand for such products is continually growing, with new countries coming on line.  StarFish sees potential increased demand for testing services, especially with the Food and Drug Administration in the U.S. asking for more testing than ever.  With an aging population in developed countries and rapid expansion of healthcare systems in developing nations, the cardiovascular healthcare sector is expanding substantially.  Medical devices are estimated to grow 5% yearly in the United States, their largest world market, over the next five years (Business Monitor International).

The two partners originally built the ViVitro test equipment to evaluate a new valve developed at the Royal Jubilee Hospital's Cardiac Development Lab in the mid-1970s.  The first prototype of their laboratory pump and model heart was constructed using a VW piston.  From there the partners evolved it into the sophisticated, market leading test equipment it has become today.

Scotten and Walker welcome StarFish Medical taking over their products and services, since the two companies have developed a close working relationship.  StarFish has been assembling ViVitro equipment for two years and is currently in production for new orders. 

ViVitro has customers in twenty countries including the U.S.A., Canada, Australia, Brazil, Japan, Singapore, and several European countries.

About ViVitro Systems
ViVitro Systems Inc. is a privately held company that was founded out of research at Royal Jubilee Hospital in 1983 by David Walker, Ph.D. and Lawrence Scotten, Dipl.T.

ViVitro makes two main products, a fatigue tester for assessing the durability of prosthetic mechanical and biological heart valves, and a laboratory model heart flow tester used primarily in medical research.  The company also offers prosthetic heart valve testing services.

About StarFish Medical
For more than ten years, StarFish has provided practical and innovative solutions in all aspects of medical device design and manufacturing, from product definition and technical engineering to formal product development and volume production in a quality environment. StarFish, an ISO 13485 certified company, provides practical turnkey to medical device companies all over North America.  The company’s cross-functional team offers expertise in engineering physics, electronics, software, firmware, mechanical engineering, industrial design and manufacturing transfer.  More information is available at StarFish Medical.

For more information contact:
Scott Phillips, President
www.starfishmedical.com
250.388.3537

Victoria, BC – StarFish Medical is proud to announce the appointment of John Walmsley as Product Development Manager.

John brings 17 years of experience in product development and manufacturing transfer to the role.  For the past three years, he has been an integral part of the StarFish Medical product development team that helps companies bring their medical products to market.  Prior to joining StarFish, he spent six years in various R&D Engineering roles at Hewlett Packard and eight years at JDS Uniphase working as a design engineer and later as product manager for high-power, fibre-optic, laser devices.

“John’s combination of deep technical expertise and exceptional people skills have been of great benefit to StarFish and our clients over the past three years.  I am delighted to see him stepping into this role as leader of the product development team and look forward to him continuing to build on our strong client relationships.”

John will be responsible for managing product development execution including client relationship management, project oversight, technical decision making, documentation, testing and ensuring conformance to our ISO13485 medical quality system.

John holds a Master of Science in Optoelectronics & Optical Information Processing from Queen’s University Belfast and a Bachelor of Science (with Honours) in Physics from the University of Bristol.  John is certified as a Chartered Physicist in the United Kingdom and a Professional Physicist in Canada.

For more information
Scott Phillips, President

http://www.starfishmedical.com
250.388.3537

PORTLAND, OR – Home Dialysis Plus, Ltd (HD+) announces a strategic partnership with StarFish Medical (Victoria, BC) to provide product development and system integration services for its home hemodialysis unit.  The partnership will dramatically accelerate the development cycle and time to market for the system.

Intended to offer patients the option to experience nightly nocturnal treatment, the HD+ system is expected to meet the needs of patients and caregivers with a cost-effective treatment option that easily integrates into their daily lives.

“With an increasing focus on home healthcare as an affordable and efficient treatment option, HD+ expects to offer patients the ability to track and manage their treatment more effectively and with improved results,” says Michael Baker, CEO, HD+.

The HD+ system is intended to provide patients with a slower, gentler nocturnal dialysis treatment that will reduce their post-treatment recovery time. Utilizing patented MECS technology and HP inkjet technology, the system is also expected to provide a smaller, more intuitive and cost-contained option than current dialysis solutions.

“We are excited to partner with HD+,” says Scott Phillips, President, StarFish Medical. “This project is a perfect match for the comprehensive technology development, product design and system integration skills at StarFish.  We are delighted to be able to contribute to the success of this important new company and their breakthrough technology.”   HD+ is the fourth new StarFish client this year in the areas of nephrology and hematology.  

About Home Dialysis Plus, Ltd.
Home Dialysis Plus, Ltd. (HD+) is focused on the advancement of home hemodialysis treatment for patients suffering from end-stage renal disease. Via the use of patented microtechnology-based energy and chemical systems (MECS) and licensed HP inkjet technology, the company aims to produce home treatment options that will offer improved health outcomes through ultra-patient-friendly, portable hemodialysis machines. More information is available at Home Dialysis Plus, Ltd.

About StarFish Medical
For more than ten years, StarFish has provided practical and innovative solutions in all aspects of medical device design and manufacturing, from product definition and technical engineering to formal product development and volume production in a quality environment. StarFish, an ISO 13485 certified company, provides practical turnkey to medical device companies all over North America.  The company’s cross-functional team offers expertise in engineering physics, electronics, software, firmware, mechanical engineering, industrial design and manufacturing transfer.  More information is available at StarFish Medical.

This news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of HD+ and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements of the plans, strategies and objectives of management for future operations; any statements concerning expected development, performance or market share relating to products and services; anticipated operational and financial results; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. HD+ assumes no obligation and does not intend to update these forward-looking statements.

Editorial Contacts:

Brenda Edin
Home Dialysis Plus, Ltd.
Portland, OR

503.528.6296

Scott Phillips
StarFish Medical
Victoria, BC

250.388.3537

Victoria, BC - APEG BC’s recent Innovation magazine highlighted StarFish Medical as a major player in BC’s medical device consulting field. Scott Phillips, StarFish Medical, President attributes the success to a “team of renaissance engineers who are curious and have a first principle approach to development.“ StarFish is currently involved in 16 projects across North America.

Read the complete article here.

For more information:
Scott Phillips
StarFish Medical

www.starfishmedical.com
(250) 388-3537

VANCOUVER, BC - Biolux Research Ltd. announced today that it has received approval from Health Canada to market the OsseoPulse Bone Regeneration System in Canada. The OsseoPulseTM is classified by Health Canada as a Class II medical device, and received a Medical Device Licence for the system and its components. The licence was applied for in partnership with StarFish Medical of Victoria, BC.

"Issue of the licence from Health Canada is a key milestone in our plan to commercialize the OsseoPulseTM product. It enables marketing and sales of the product directly in Canada, as well as establishes county of origin approval to support export to overseas markets," states Kevin Strange, President and CEO of Biolux. "We look forward to introducing the OsseoPulseTM to the Canadian market at dental implant and regeneration conferences in the third quarter of this year, and to the Korean market with our distribution partner DIO Implant."

About Biolux Research
Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research and is well positioned to release its OsseoPulse? system to the marketplace in 2008. Its proprietary, patent pending OsseoPulse? Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

About DIO Implant
DIO Implant is a subsidiary of Dong Seo Inc. (DSI), a KOSDAQ exchange listed company with a market value approximately 160 Million US dollars. DIO implant is one of the best selling implant systems in Korea. DSI supplies DIO dental implant systems to more than 30 dental hospitals and 2,000 dental clinics and has over 13% of Korean domestic market share. DSI also exports the DIO dental implant system to number of countries including Australia, Vietnam, China, Mexico and the USA. For more information please visit: www.dio.co.kr/en/

About StarFish Medical
Starfish Medical is a leading specialist firm in contract medical device development and manufacturing. For over 10 years StarFish Medical has designed, developed and manufactured sophisticated medical devices for a select clientele. StarFish is an ISO 13485 certified developer and manufacturer of high technology medical products on contract and joint venture basis. www.starfishmedical.com

For more information
Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120

Vancouver, BC - Pyng Medical Corp. (PYT: TSX .V) today announced the Company is receiving non-repayable research support from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to accelerate the development and commercialization of the Company's second generation Intraosseous Infusion System.

Based on the market-leading performance of the Company's lead clinical product, FAST1, NRC will contribute approximately $128,000 to support the development of the next generation medical device over the time of the research and development project. FAST1 is currently the most rapid, reliable and safe alternative to conventional intravenous infusion providing lifesaving vascular access for fluid and drug resuscitation in shock and trauma victims.

The NRC Industrial Research Assistance Program (NRC-IRAP) is the Government of Canada's best tool for helping small and medium-sized firms develop new technologies that result in the commercialization of new products, processes or markets. NRC-IRAP's technology and business advisory network, coupled with the shared financial support it offers to innovative companies and organizations, strengthens Canada's innovation system and ignites the growth of NRC's technology cluster initiatives in Canada. NRC employs close to 4,000 people across Canada, providing substantial resources to help Canada become one of the world's top five R&D performers by 2010.

"The financial support from the Government of Canada through the NRC-IRAP program is critical for us to complete our research and develop our next generation products allowing us to exploit the true market opportunity for Pyng's proprietary technology platform," said David Christie, President and CEO. "Since entering into a development agreement with Starfish Medical in the first quarter of last year we have completed the feasibility work on our prototype system and look forward to commercially launching the state-of-the-art FASTX by year-end."

"In parallel, we are also pursuing in-licensing and acquisition opportunities to expand our portfolio of life-saving resuscitation products serving large critical care markets in military, hospital and emergency medical service applications internationally," adds Christie.

About Pyng Medical Corp.
Pyng Medical Corporation is a Canadian medical device company that developed and commercially launched its proprietary, award-winning FAST1 Intraosseous Infusion System. The Company's audited fiscal 2007 year end results demonstrated 60% revenue growth compared to fiscal 2006 and more than a ten-fold increase in income. Pyng reported record sales of $4,807,705 with net income after tax of $858,788 or 18% of sales. In fiscal 2007, the Company achieved consecutive quarterly revenue growth and profits throughout the year.

Pyng was selected in the "2007 TSX Venture 50" Top 10 companies in Life Sciences, based on solid financial metrics for the year ending December 31, 2006. With expanding markets in North America, Europe and Asia, the FAST1 has worldwide application for use in hospitals, emergency medical service and military.

About Starfish Medical
Starfish Medical is a leading specialist firm in contract medical device development and manufacturing. For over 10 years StarFish Medical has designed, developed and manufactured sophisticated medical devices for a select clientele. StarFish, based in Victoria, BC was chosen for their ability to provide turnkey medical device design solutions under their ISO 13485 Quality System and their experience with precision mechanical parts and plastic materials.